Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL.
CalciMedica, Inc., La Jolla, CA; and.
J Immunol. 2021 Sep 1;207(5):1275-1287. doi: 10.4049/jimmunol.2100127. Epub 2021 Aug 13.
The airway epithelial cells (AECs) lining the conducting passageways of the lung secrete a variety of immunomodulatory factors. Among these, PGE limits lung inflammation and promotes bronchodilation. By contrast, IL-6 drives intense airway inflammation, remodeling, and fibrosis. The signaling that differentiates the production of these opposing mediators is not understood. In this study, we find that the production of PGE and IL-6 following stimulation of human AECs by the damage-associated molecular pattern extracellular ATP shares a common requirement for Ca release-activated Ca (CRAC) channels. ATP-mediated synthesis of PGE required activation of metabotropic P2Y receptors and CRAC channel-mediated cytosolic phospholipase A signaling. By contrast, ATP-evoked synthesis of IL-6 occurred via activation of ionotropic P2X receptors and CRAC channel-mediated calcineurin/NFAT signaling. In contrast to ATP, which elicited the production of both PGE and IL-6, the uridine nucleotide, UTP, stimulated PGE but not IL-6 production. These results reveal that human AECs employ unique receptor-specific signaling mechanisms with CRAC channels as a signaling nexus to regulate release of opposing immunomodulatory mediators. Collectively, our results identify P2Y receptors, CRAC channels, and P2X receptors as potential intervention targets for airway diseases.
气道上皮细胞 (AECs) 排列在肺部的传导通道中,分泌多种免疫调节因子。其中,PGE 限制肺部炎症并促进支气管扩张。相比之下,IL-6 会引发强烈的气道炎症、重塑和纤维化。区分这些相反介质产生的信号机制尚不清楚。在这项研究中,我们发现,损伤相关分子模式细胞外 ATP 刺激人 AECs 后,PGE 和 IL-6 的产生都需要 Ca 释放激活的 Ca(CRAC)通道。ATP 介导的 PGE 合成需要激活代谢型 P2Y 受体和 CRAC 通道介导的细胞质磷脂酶 A 信号转导。相比之下,ATP 引发的 IL-6 合成通过离子型 P2X 受体和 CRAC 通道介导的钙调神经磷酸酶/NFAT 信号转导发生。与同时引发 PGE 和 IL-6 产生的 ATP 不同,尿嘧啶核苷酸 UTP 刺激 PGE 但不刺激 IL-6 产生。这些结果表明,人 AECs 采用独特的受体特异性信号机制,以 CRAC 通道作为信号枢纽,调节相反的免疫调节介质的释放。总之,我们的结果确定 P2Y 受体、CRAC 通道和 P2X 受体作为气道疾病的潜在干预靶点。